PDCD1 and non-small cell lung carcinoma: Currently, the CD73 antibody inhibitor furthest along in clinical development is Oleclumab, which is currently in a phase III trial (PACIFIC-9, NCT05221840) in combination with durvalumab, a programmed cell death protein 1 (PD-1) inhibitor, for non-small cell lung cancer (NSCLC) (Barlesi et al., 2024).